Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial-Reference-Cited by-同舟云学术

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial

Published:2023-01-21 Issue:9 Volume:149 Page:6171-6179
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Alsaleh K.,Al Zahwahry H.,Bounedjar A.,Oukkal M.,Saadeddine A.,Mahfouf H.,Bouzid K.,Bensalem A.,Filali T.,Abdel-Razeq H.,Larbaoui B.,Kandil A.,Abulkhair O.,Al Foheidi M.,Ghosn M.,Rasool H.,Boussen H.,Mezlini A.,Haddaoui A.,Ayari J.,Al Ghamdi M.,Errihani H.,Abdel-Aziz N.,Arafah M.,Dabouz F.,Bahadoor M.,Kullab S.,Nabholtz J. M.,

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00432-023-04588-3.pdf

Reference33 articles.

1. Ács B, Zámbó V, Vízkeleti L, Szász AM, Madaras L, Szentmártoni G et al (2017) Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy. Diagn Pathol 12(1):1–12

2. Allevi G, Strina C, Andreis D, Zanoni V, Bazzola L, Bonardi S et al (2013) Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. Br J Cancer 108(8):1587–1592

3. AlSaleh KA (2021) Clinical trials before, during, and after COVID-19 Pandemic. Am J Clin Oncol 44(2):90–91

4. AlSaleh K, Al Zahwahry H, Bounedjar A, Oukkal M, Saadeddine A, Mahfouf H et al (2021) Response to induction neoadjuvant hormonal therapy using upfront 21-gene breast recurrence score assay—results from the SAFIA phase III trial. JCO Global Oncol 7:811–819

5. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N et al (2016a) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17(4):425–439

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant and neoadjuvant therapy with or without CDK4/6 inhibitors in HR+/HER2- early breast cancer: a systematic review and meta-analysis;Frontiers in Pharmacology;2024-09-12

2. Reporting on patient’s body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review;Breast Cancer Research;2024-05-22

3. Hematological toxicity of cyclin-dependent kinase 4/6 inhibitors in patients with breast cancer: a network meta-analysis and pharmacovigilance study;Expert Opinion on Drug Safety;2024-05-16

4. Cyclin-Dependent Kinase 4/6 Inhibitors as Neoadjuvant Therapy of Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: What do we Know so Far?;Clinical Breast Cancer;2024-04

5. Reporting on invasive lobular breast cancer in clinical trials: a systematic review;npj Breast Cancer;2024-03-20